Photo Gallery
Kenya Scientists in Diaspora members with Education Attache Andrew Buop at Kenya Embassy in Wshington D.C. (seated extreme left) at a Dinner function during the KESSA Conference 2024 in Atlanta, Georgia, USA.
Fidelis Ndombera of Kenya Scientists in Diaspora presentation at the KESSA Conference 2024 in Atlanta, Georgia, USA.
Sports Science Professors and Kenya Scientists in Diaspora members during the KESSA Conference 2024 in Atlanta, Georgia, USA.
ON 27Sep2024, Kenyan Scientists in Diaspora Team Leader joined Yunigen Inc. and the West Virginia University community in Morgantown, USA, for the launch of Scedamin, the first pediatric formulation of hydroxyurea developed by Yunigen for the treatment of Sickle Cell Disease. This significant milestone is especially timely as it coincides with National Sickle Cell Awareness Month in September.
Sickle Cell Disease remains a pressing public health challenge, particularly in Africa, where the burden is greatest. Each year, of the 300,000 to 500,000 children born with Sickle Cell Disease, over 250,000 are in sub-Saharan Africa. Sadly, the mortality rate among these children is alarmingly high, with 50-90% not surviving past the age of five, making the disease an invisible yet devastating health crisis in the region.
The Chief Guest was Kenyan Foreign & Diaspora affairs Cabinet Secretary Wycliffe M. Mudavadi and was humbled by his appreciation of Kenyan Scientists in Diaspora and their concerted pursuit to contribute to global medical solutions.
